TribLIVE

| News

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Newsmaker: Dr. Anette Duensing

Email Newsletters

Click here to sign up for one of our email newsletters.
Anette Duensing, 43, M.D. recently received funding from the GIST Cancer Research Fund — a patient-driven organization that funds research on gastrointestinal stromal tumors, or GISTs. This is the seventh year in a row that the research fund supports research in Duensing’s laboratory.

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

Friday, Sept. 7, 2012, 12:01 a.m.
 

Dr. Anette Duensing

Noteworthy: Duensing received funding from the GIST Cancer Research Fund — a patient-driven organization that funds research on gastrointestinal stromal tumors, or GISTs. This is the seventh consecutive year that the fund has supported research in Duensing's laboratory.

Age: 43

Residence: O'Hara

Family: Husband, Stefan

Occupation: Assistant professor of pathology, University of Pittsburgh School of Medicine

Background: In 2000, during her postdoctoral fellowship at Brigham and Women's Hospital in Boston, Duensing experienced firsthand the tumor remission of the first GIST patient treated with the therapy drug Gleevec. Since then, her research has focused on a better molecular understanding of the biology of GISTs and the mode of action of Gleevec. Duensing joined the University of Pittsburgh Cancer Institute in 2003.

Education: Medical degree from the University of Hannover Medical School, Hannover, Germany, in 1997

Quote: “This generous funding has allowed us to significantly expand our efforts identifying novel treatment options for GIST patients — in particular for patients whose tumors have become resistant to Gleevec over time.”

— Chris Togneri

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Allegheny

  1. Peduto blasts Wolf’s plan to borrow $3B to shore up pensions
  2. Derry boy recovering at home after high-profile intestinal transplant
  3. Pittsburgh is planning to add network of bike lanes through Oakland
  4. School credit ratings a problem for several in Western Pennsylvania
  5. Public Utility Commission will consider Yellow Cab fare hikes
  6. Fugitive arrested at Plum motel on drug, gun charges
  7. Rising East Liberty out of reach for Pittsburgh’s poor
  8. Judge adds 2 years to sentence of Baldwin Borough man acquitted of murder
  9. Dormont, Millvale want grocers closer to home
  10. Newsmaker: Jesabel I. Rivera-Guerra
  11. Former Penn Hills football player found not guilty of homicide